DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Study DC-6001-101 Part B is a multicenter, open-label, Phase 1 study to assess the effects of
anti-CD93 mAb (DCSZ11) as a monotherapy in patients with advanced or metastatic solid tumors.